AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|
20.3 C
New York
Friday, November 6, 2026

Tag: Regulatory

newsFORsourcecompanycontentinformationreleases1market

Eddid Financial and EXIO Limited Forge Strategic Partnership To Drive Virtual Asset Market Growth

HONG KONG, June 23, 2025 /PRNewswire/ -- Eddid Financial, a leading fintech-driven financial services group, and EXIO Limited, a licensed virtual asset trading platform...

APP Group Shares Paperboard Advancements Amid U.S. Biodegradable Packaging Market Growth

JAKARTA, Indonesia , June 23, 2025 /PRNewswire/ -- As proud members of the Paperboard Packaging Council (PPC), APP Group (APP) and Charta Global Inc., its...

Kinterra Capital Submits Proposal to Acquire 100% of New World Resources

TORONTO and PERTH, Australia, June 23, 2025 /PRNewswire/ -- Kinterra Capital GP Corp. II ("Kinterra"), in its capacity as general partner of the Kinterra...

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

GoNetZero and Anvil Analytical Collaborate to Strengthen Carbon Tracking Across Global Supply Chains

SINGAPORE and LONDON, June 23, 2025 /PRNewswire/ -- GoNetZero, a global decarbonisation enabler in clean energy procurement and carbon management, is pleased to announce...

GoNetZero and Anvil Analytical Collaborate to Strengthen Carbon Tracking Across Global Supply Chains

SINGAPORE and LONDON, June 23, 2025 /PRNewswire/ -- GoNetZero, a global decarbonisation enabler in clean energy procurement and carbon management, is pleased to announce...

Unleash Your Inner Investor: Jessie Harper’s Take on Tesla’s Potential

Hey there, fabulous money mavens! 💁‍♀️ Let's dive into the world of Tesla and the optimistic forecasts made by Cathie Wood's Ark Invest. If...

Ethereum Price Prediction: ETH To Dominate SOL For H2 2025, Is Remittix The Best ETH-Based Crypto To Buy Now?

New York, June 23, 2025 (GLOBE NEWSWIRE) -- The crypto arena is heating up as Ethereum and Solana lock horns in a high-stakes battle for dominance. With institutional money pouring into blockchain infrastructure and the SEC now reviewing ETF proposals for both assets, the stage is set for a dramatic showdown. Could ETH leave SOL in the dust by late 2025? Let’s unpack the data, including why projects like Remittix might be the smartest ETH-based bets right now.

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Fletcher Zone Maiden Mineral Resource of 2.3Moz

Stage 1 Fletcher Resource almost doubles the current Beta Hunt Resource PERTH, Western Australia, June 23, 2025 /CNW/ - Westgold Resources Limited (ASX: WGX) (TSX: WGX)...

Steelmaker SSAB, the manufacturer of Hardox® wear plate, cracks down on counterfeit goods

MELBOURNE, Australia, June 23, 2025 /PRNewswire/ -- SSAB has taken decisive action against two Indian companies selling counterfeit steel. The unauthorised products, labelled with...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers